Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy
Hess GP, Natarajan P, Faridi KF, Fievitz A, Valsdottir L, Yeh RW. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy. Circulation 2017, 136: 2210-2219. PMID: 29084735, PMCID: PMC5716860, DOI: 10.1161/circulationaha.117.028430.Peer-Reviewed Original ResearchMeSH KeywordsAdministrative Claims, HealthcareAgedAtherosclerosisCost-Benefit AnalysisDrug CostsElectronic Health RecordsEligibility DeterminationFemaleHumansHyperlipoproteinemia Type IIHypolipidemic AgentsInsurance, Health, ReimbursementInsurance, Pharmaceutical ServicesMaleMedicareMiddle AgedPCSK9 InhibitorsProcess Assessment, Health CareProprotein Convertase 9Retrospective StudiesSerine Proteinase InhibitorsTreatment OutcomeUnited StatesConceptsProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitorsAtherosclerotic cardiovascular diseasePCSK9i prescriptionsPayer typeCardiovascular diseaseProprotein convertase subtilisin/kexin type 9 inhibitor therapyHigher low-density lipoprotein cholesterol levelsSubtilisin/kexin type 9 inhibitorsLow-density lipoprotein cholesterol levelsClinical atherosclerotic cardiovascular diseaseDrug's high costNonprimary care providersLipoprotein cholesterol levelsDescriptive cohort studyElectronic medical recordsPCSK9i therapyPrescription approvalThird-party payersStatin useClinical characteristicsStatin intoleranceCohort studyInhibitor therapyPharmacy claimsPrescription claims